{"_id": "64fe7d6a1544b4d920499cfc", "nctID": "NCT03137693", "booleanRepresentation": "{\n    \"$and\":[\n        {\n            \"$and\": [\n                {\"Understand and voluntarily sign an informed consent document prior to conducting any study related assessments or procedures.\"},\n                {\"Histologically proven invasive adenocarcinoma of breast.\"},\n                {\"Must have marker clip indicating location of target tumor in breast.\"},\n                {\"Unifocal tumor less than or equal to 2 cm based on contrast-enhanced prone-breast MRI.\"},\n                {\"Must be clinically and radiographically node negative (N0) to participate on this protocol. Clinically suspicious regional nodes by imaging or physical exam require biopsy evaluation to exclude disease involvement.\"},\n                {\"Appropriate candidate for breast-conserving surgery based on multi-disciplinary assessment.\"},\n                {\"Females age \u2265 50 years.\"},\n                {\"Able to tolerate prone body positioning during radiation therapy.\"},\n                {\"No prior ipsilateral-breast or thoracic radiotherapy.\"},\n                {\"As defined on MRI, target lesion must be at least 10 mm distance from skin (defined as volume encompassing first 3 mm from breast surface).\"},\n                {\"Must be estrogen receptor (ER) positive.\"},\n                {\"Must be negative for Her-2 amplification. (Either 1+ on semi-quantitative evaluation of immunostain or negative by fluorescent in-situ hybridization).\"},\n                {\"No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery in the investigator's opinion.\"},\n                {\"No history of an invasive malignancy (other than this breast cancer, or non-metastatic basal or squamous skin cancers) in the last 5 years.\"},\n                {\"Must not have received nor be planned for neoadjuvant chemotherapy prior to SABR or surgery.\"},\n                {\"ECOG performance status less than 2.\"},\n                {\"Females of childbearing potential must have a negative urine pregnancy test prior to simulation and within seven days of SABR start.\"}\n            ]\n        },\n        {\n            \"$not\": {\n                \"$or\": [\n                    {\"Have invasive lobular carcinoma.\"},\n                    {\"Have a Tumor > 2 cm as measured on prone contrast-enhanced breast MRI.\"},\n                    {\"Have presence of histologically proven lymph node disease.\"},\n                    {\"Are not a candidate for breast conserving surgery.\"},\n                    {\"Have had prior ipsilateral-breast or thoracic radiotherapy.\"},\n                    {\"History of scleroderma or lupus erythematosus with either cutaneous manifestation or requiring active treatment.\"},\n                    {\"An MRI defined target tumor that is within 10 mm of skin (defined as volume encompassing first 3 mm from skin surface).\"},\n                    {\"Have amplification of Her-2 (Either 3+ by semi-quantitative immunostain or positive by Fluorescent in-situ hybridization (FISH)).\"},\n                    {\"Have implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery in the investigator's opinion.\"},\n                    {\"History of an invasive malignancy (other than this breast cancer, or non-metastatic basal or squamous skin cancers) in the last 5 years.\"},\n                    {\"Have received or plan to receive neoadjuvant chemotherapy either before radiotherapy or before surgery.\"},\n                    {\"A known carrier of BRCA1 or BRCA2 gene mutation.\"},\n                    {\"Pregnant or unwilling to undergo pregnancy screening.\"}\n                ]\n            }\n        }\n    ]\n}"}